Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A Clinical Trial

Official title:

A Phase I, Open-label, Ascending Dose Study to Determine the Safety and Reactogenicity of a Wild Type Seasonal A/California/ H1N1 2009 Influenza Challenge Virus in Healthy Volunteers, Following a Single Intranasal Administration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02014870
• Other study ID #: H1N1_CS_01
• Secondary ID: 2013-002503-34
• Status: Completed
• Phase: Phase 1
• First received: December 5, 2013
• Last updated: December 12, 2013
• Start date: June 2013
• Est. completion date: October 2013

Study information

• Verified date: December 2013
• Source: Immune Targeting Systems Ltd
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP
• Study type: Interventional

Clinical Trial Summary

The primary objective is to determine the dose level of live, wild-type A/California/ H1N1 2009 virus that has an appropriate safety and illness/infectivity profile to be used as an influenza virus, challenge strain in future intervention studies.

Illness parameters were collected by subject symptom scores as well as by physical examination. Virus parameters were measured by PCR and cell culture assay (performed by VisMederi srl).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Male or female aged 18-45 years inclusive.

2. Able to give written informed consent to participate.

3. Healthy, as determined by medical history, physical examination, vital signs, 12 lead ECG, and clinical safety laboratory examinations at baseline, as determined by the Investigator.

4. Absent or low levels of detectable pre-existing antibodies to influenza virus subtypes, including as a minimum the challenge strain, as determined by an HAI titre of = 10 prior to challenge.

5. Non-habitual smoker (habitual smokers are persons who smoke more than 4 cigarettes or other tobacco products on a weekly basis) and agree to not use tobacco products during participation in the study.

6. Females should fulfil one of the following criteria:

1. At least one year post-menopausal;

2. Surgically sterile;

3. Will use oral, implantable, transdermal or injectable contraceptives for 30 days prior to administration of the A/California/H1N1 2009 virus until the follow-up visit is performed.

4. Use another reliable form of contraception approved by the Investigator (e.g., intrauterine device, female condom, diaphragm with spermicide, cervical cap, use of condom by the sexual partner or a sterile sexual partner) from the time of screening until the follow up visit is performed.

5. Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1.

7. Comprehension of the study requirements, expressed availability for the required study period, and ability to be quarantined for up to 10 days and to attend the scheduled follow-up visit.

8. Negative alcohol and urine drug screening tests prior to entering quarantine.

9. Being willing to adhere to the prohibitions and restrictions specified in this protocol

Exclusion Criteria:

1. Prior receipt of any influenza vaccine for the previous 2 years.

2. Significant adulthood history of seasonal hay fever or a seasonal allergic rhinitis or perennial allergic rhinitis or chronic or nasal or sinus condition such as chronic sinusitis.

3. Abnormal nasal structure including septal deviation and nasal polyps.

4. Suffering from asthma, bronchiectasis, emphysema, chronic obstructive pulmonary disease or any other chronic lung disease.

5. Pregnant or who is breast feeding.

6. Diastolic BP < 50 or > 90 mmHg, a systolic BP < 100 or > 150 mmHg, a pulse < 50 or > 100 bpm after resting for 5 min.

7. Current use or use within the last 7 days of intranasal corticosteroids.

8. Presence of significant uncontrolled medical, neurological or psychiatric illness (acute or chronic) as assessed by the Investigator. This includes, but is not limited to, institution of new surgical or medical treatment (for a chronic condition), or a significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months of screening and reconfirmed on Day -1 prior to challenge.

9. Positive serology for HIV-1 or HIV-2, or HBsAg or HCV antibodies.

10. Cancer or treatment for cancer, within 3 years, excluding basal cell carcinoma of the skin, which is allowed.

11. Presence of immunosuppression or any medical condition that may be associated with impaired immune responsiveness, including, but not limited to, diabetes mellitus inflammatory bowel disease.

12. Presently receiving (or history of receiving) or during the preceding 3-month period prior to screening, any medications or other treatments that may adversely affect the immune system such as allergy injections, immune globulin, interferon, immunomodulators, cytotoxic drugs or other drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable) azathioprine or mercaptopurine. Topical corticosteroids except intranasal will be allowed.

13. Anticipated presence of a household contact with documented severe immunosuppression (as defined by CD4 < 200/mm³ or an absolute neutrophil count < 1500/mm³), either as a result of disease and/or therapy.

14. Anticipated presence of a household contact age 5 years or younger, within 2 weeks following challenge.

15. Anticipated presence of a household contact age 65 years or older, within 2 weeks following challenge.

16. Current professional activity as a carer or healthcare workers who will return to work within 2 weeks following challenge.

17. Anticipated presence of a pregnant household contact, within 2 weeks following challenge.

18. History of anaphylactic type reaction to egg or egg protein.

19. History of Guillain-Barré syndrome.

20. History of drug or chemical abuse in the year before the study.

21. Receipt of any investigational virus product or nonregistered drug within the 30 days prior to challenge or currently enrolled in any investigational drug study or intends to enrol in such a study within the ensuing study period.

22. Receipt of blood or blood products 6 months prior to challenge or planned administration during the study period.

23. Blood donation in the last 12 weeks.

24. Acute disease within 72 h prior to challenge, defined as the presence of a moderate or severe illness with or without fever (as determined by the Investigator through medical history and physical examination), or presence of a fever = 38ºC oral.

25. Elevated white cell count above 10.5 x 109/L or an absolute neutrophil count above 7.5 x 109/L.

26. Any condition that, in the opinion of the Investigator, might interfere with the primary study objective.

27. Habitual smoker (habitual smokers are persons who smoke more than 4 cigarettes or other tobacco products on a weekly basis).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Influenza A
• Influenza, Human

Intervention

Other:
• 1:1000 Live wild-type A/California/H1N1 2009
1:1000 dilution of neat virus
• 1:100 Live wild-type A/California/H1N1 2009
1:100 dilution of neat virus
• 1:10 Live wild-type A/California/H1N1 2009
1:10 dilution of neat virus

Locations

Country	Name	City	State
Belgium	SGS Life Sciences	Antwerpen

Sponsors (1)

Lead Sponsor	Collaborator
Immune Targeting Systems Ltd

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	Frequency and severity of treatment-emergent adverse events as a measure of which dose of H1N1 challenge virus is safe for future intervention studies	Day 1 - 29	Yes
Primary	Infectivity	Frequency and severity of influenza signs and symptoms experienced and incidence of laboratory confirmed infections, as a measure of which dose of H1N1 virus induces an appropriate level of illness/ infectivity for future intervention studies	Day 1- 8	No
Secondary	Kinetics	Record influenza signs, symptoms, and viral load/shedding over time to assess kinetics of infection	Day 1 -8	No
Secondary	Immunology	Assess immunological responses over the study period, including; humoral immune response to challenge virus; cell mediated immune responses to virus proteins, including those specific for ITS' influenza A vaccine peptides;	Day 1 - 29	No
Secondary	Biomarkers	investigate gene expression to explore potential markers of influenza A infection that may be used in future intervention studies and, as such, determine mechanisms of vaccine efficacy	Day 1 -29	No